ETX: e-therapeutics plc - Summary | Jitta

e-therapeutics plc

LON:ETX

Notice
Stock data is unavailable or the company’s delisted.
Price
£0.09
Loss Chance
58.4%
0.32JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (1)
Recent Business Performance (11)
Financial Strength (40)
Return to Shareholders (0)
Competitive Advantage (9)
Jitta Signs
Revenue and EarningEarning loss detected in 2024
Operating MarginDeclined
Recent Business PerformanceEarning decline 22.28% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
0.32
100.00%
1.57
103.81%
1.57
103.81%
4.06
79.51%
4.12
55.68%
4.58
79.57%
COMPANY DESCRIPTION
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.